Thiabendazole vs. albendazole in treatment of toxocariasis: a clinical trial.

Stürchler, D; Schubarth, P; Gualzata, M; Gottstein, Bruno; Oettli, A (1989). Thiabendazole vs. albendazole in treatment of toxocariasis: a clinical trial. Annals of tropical medicine and parasitology, 83(5), pp. 473-478. Maney 10.1080/00034983.1989.11812374

Full text not available from this repository. (Request a copy)

Between 1986 and 1988, 34 patients (age range six to 83 years) with visceral or ocular larva migrans were randomly assigned to a five-day treatment with thiabendazole 2 x 25 mg kg-1 day-1 (15 patients) or albendazole 2 x 5 mg kg-1 day-1 (19 patients). On the fifth treatment day, six patients (40%) in the thiabendazole group and 11 patients (58%) in the albendazole group showed excellent or good drug tolerability. Efficacy of treatment was assessed after 30 weeks (range six to 56 weeks). In the thiabendazole group, median eosinophilia remained at 14% and four patients (27%) were clinically cured. In the albendazole group, the median eosinophilia decreased from 10 to 3.5% and six patients (32%) were clinically cured. We recommend albendazole for treatment of visceral and ocular larva migrans with a minimum dose of 10 mg kg-1 daily for five days.

Item Type:	Journal Article (Original Article)
Division/Institute:	05 Veterinary Medicine > Department of Infectious Diseases and Pathobiology (DIP) > Institute of Parasitology 05 Veterinary Medicine > Department of Infectious Diseases and Pathobiology (DIP)
UniBE Contributor:	Gottstein, Bruno
Subjects:	600 Technology > 610 Medicine & health 600 Technology > 630 Agriculture
ISSN:	0003-4983
Publisher:	Maney
Language:	English
Submitter:	Bruno Gottstein
Date Deposited:	18 Jul 2018 12:14
Last Modified:	05 Dec 2022 15:16
Publisher DOI:	10.1080/00034983.1989.11812374
PubMed ID:	2694978
URI:	https://boris.unibe.ch/id/eprint/118643